Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects

A Randomized, Double-Blind, Placebo- and Moxifloxacin (Open-Label)-Controlled, 4-Period Crossover Study of the Effects of a Single Dose of MOA-728 Infused Intravenously on Cardiac Repolarization in Healthy Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00434395

Enrollment

Unknown

Registered

2007-02-13

Start date

2007-03-31

Completion date

2007-10-31

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The purpose of the study is to assess the effects of MOA-728 on cardiac repolarization in healthy subjects.

Interventions

DRUGMOA-728

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Generally healthy subjects men or women aged 18-50

Exclusion criteria

* Any significant clinically important disease * Family history of long QT syndrome and/or sudden cardiac death * Allergy to moxifloxacin or the quinolone class of antibiotics

Design outcomes

Primary

Measure	Time frame
Cardiac repolarization will be assessed by the QTc interval in healthy subjects.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026